Literature DB >> 28288539

Ischemia-modified albumin as a marker of vascular dysfunction and subclinical atherosclerosis in β-thalassemia major.

Amira Abdel Moneam Adly1, Nayera Hazaa Khalil ElSherif1, Eman Abdel Rahman Ismail2, Yosra Abdelzaher Ibrahim3, Gamal Niazi3, Sara Hamed Elmetwally1.   

Abstract

BACKGROUND: Ischemia-modified albumin (IMA) is an altered type of serum albumin that forms under conditions of oxidative stress and an independent predictor of major adverse cardiovascular events.
OBJECTIVES: To measure the levels of IMA in 45 children and adolescents with β-thalassemia major (β-TM) compared with 30 healthy controls and assess its relation to lipid peroxidation, vascular complications and subclinical atherosclerosis.
METHODS: β-TM patients without symptoms of heart disease were studied focusing on transfusion history, chelation therapy, serum ferritin, malondialdehyde (MDA) and IMA levels. Echocardiography was performed and carotid intima media thickness (CIMT) was assessed.
RESULTS: IMA and MDA levels were significantly higher in β-TM patients compared with controls (p < 0.001). IMA was higher among patients with heart disease, pulmonary hypertension risk and serum ferritin ≥2500 µg/l than those without. TM patients compliant to chelation had significantly lower IMA levels. IMA levels were positively correlated to MDA and CIMT while negatively correlated to ejection fraction and fractional shortening.
CONCLUSION: Our results highlight the role of oxidative stress in the pathophysiology of vascular complications in thalassemia. IMA could be useful for screening of β-TM patients at risk of cardiopulmonary complications and atherosclerosis because its alteration occurs in early subclinical disease.

Entities:  

Keywords:  CIMT; Thalassemia; ischemia-modified albumin; malondialdehyde; oxidative stress; vascular dysfunction

Mesh:

Substances:

Year:  2017        PMID: 28288539      PMCID: PMC6837380          DOI: 10.1080/13510002.2017.1301624

Source DB:  PubMed          Journal:  Redox Rep        ISSN: 1351-0002            Impact factor:   4.412


  69 in total

1.  Pulmonary hypertension in thalassemia.

Authors:  Claudia R Morris; Elliott P Vichinsky
Journal:  Ann N Y Acad Sci       Date:  2010-08       Impact factor: 5.691

2.  Effects of balloon occlusion during percutaneous coronary intervention on circulating Ischemia Modified Albumin and transmyocardial lactate extraction.

Authors:  M K Sinha; J M Vazquez; R Calvino; D C Gaze; P O Collinson; J C Kaski
Journal:  Heart       Date:  2006-12       Impact factor: 5.994

Review 3.  Pulmonary hypertension associated with hemoglobinopathies: prevalent but overlooked.

Authors:  Dimitrios Farmakis; Athanasios Aessopos
Journal:  Circulation       Date:  2011-03-22       Impact factor: 29.690

4.  Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.

Authors:  Alessia Pepe; Antonella Meloni; Marcello Capra; Paolo Cianciulli; Luciano Prossomariti; Cristina Malaventura; Maria Caterina Putti; Alma Lippi; Maria Antonietta Romeo; Maria Grazia Bisconte; Aldo Filosa; Vincenzo Caruso; Antonella Quarta; Lorella Pitrolo; Massimiliano Missere; Massimo Midiri; Giuseppe Rossi; Vincenzo Positano; Massimo Lombardi; Aurelio Maggio
Journal:  Haematologica       Date:  2010-09-30       Impact factor: 9.941

5.  Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia.

Authors:  D Bar-Or; G Curtis; N Rao; N Bampos; E Lau
Journal:  Eur J Biochem       Date:  2001-01

6.  Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report.

Authors:  Claudia R Morris; Hae-Young Kim; Felicia Trachtenberg; John Wood; Charles T Quinn; Nancy Sweeters; Janet L Kwiatkowski; Alexis A Thompson; Patricia J Giardina; Jeanne Boudreaux; Nancy F Olivieri; John B Porter; Ellis J Neufeld; Elliott P Vichinsky
Journal:  Blood       Date:  2011-07-19       Impact factor: 22.113

7.  Metabolic pathways related to oxidative stress in patients with hemoglobin h disease and iron overload.

Authors:  Shyh-Shin Chiou; Chao-Jung Tsao; Shih-Meng Tsai; Ye-Ru Wu; Yu-Mei Liao; Pei-Chin Lin; Li-Yu Tsai
Journal:  J Clin Lab Anal       Date:  2014-02-27       Impact factor: 2.352

8.  Ischemia modified albumin, high-sensitivity c-reactive protein and natriuretic peptide in patients with coronary atherosclerosis.

Authors:  Konstantinos Kazanis; Maria Dalamaga; Charalampos Nounopoulos; Antonios S Manolis; Nikolaos Sakellaris; Gerard Jullien; Amalia Dionyssiou-Asteriou
Journal:  Clin Chim Acta       Date:  2009-07-19       Impact factor: 3.786

9.  Maternal serum ischemia modified albumin as a marker for hypertensive disorders of pregnancy: a pilot study.

Authors:  Sapna Vyakaranam; Aparna Varma Bhongir; Dakshayani Patlolla; Rekha Chintapally
Journal:  Int J Reprod Contracept Obstet Gynecol       Date:  2015-06

Review 10.  What is new in iron overload?

Authors:  Christiane Vermylen
Journal:  Eur J Pediatr       Date:  2007-09-26       Impact factor: 3.183

View more
  5 in total

1.  Obstructive sleep apnea and the effect of CPAP treatment on ischemia-modified albumin levels: a multi effect size meta-analysis with diagnostic test accuracy.

Authors:  Seshadri Reddy Varikasuvu; Naveen Dutt; Dibakar Sahu
Journal:  Sleep Breath       Date:  2018-06-14       Impact factor: 2.816

2.  The effects of iron overload, insulin resistance and oxidative stress on metabolic disorders in patients with β- thalassemia major.

Authors:  Soheila Setoodeh; Marjan Khorsand; Mohammad Ali Takhshid
Journal:  J Diabetes Metab Disord       Date:  2020-06-03

3.  Study of ischemia modified albumin (IMA) as a biomarker in hypertensive retinopathy.

Authors:  Ecaterina Pavlovschi; Valeriana Pantea; Djina Borovic; Olga Tagadiuc
Journal:  Med Pharm Rep       Date:  2021-04-29

4.  Al-hijamah (wet cupping therapy of prophetic medicine) significantly and safely reduces iron overload and oxidative stress in thalassemic children: a novel pilot study.

Authors:  Mohamed El-Shanshory; Nahed M Hablas; Yasmin Shebl; Ahmed R Fakhreldin; Mohamed Attia; Hamdi H Almaramhy; Hussam Baghdadi; Mongi Ayat; Amal Albeihany; Amr El-Dardear; Hoda Ali Ibrahim; Hany Salah Mahmoud; Manal Mohamed Helmy Nabo; Salah Mohamed El Sayed
Journal:  J Blood Med       Date:  2018-12-14

5.  The Effect of Continuous Ventilation on Thiol-Disulphide Homeostasis and Albumin-Adjusted Ischemia-Modified Albumin During Cardiopulmonary Bypass.

Authors:  Seyda Efsun Ozgunay; Kadir Kaan Ozsin; Yasemin Ustundag; Derya Karasu; Buket Ozyaprak; Burak Balcı; Ozcan Erel; Senol Yavuz
Journal:  Braz J Cardiovasc Surg       Date:  2019-08-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.